Acadia Pharmaceuticals ACAD Total debt

Total debt at other companies

BiogenBIIB

$7.56B+14.6%

Neurocrine BiosciencesNBIX

$463.5M-6.0%

MapLight Therapeutics, Inc.MPLT

$5.59M—

Taysha Gene Therapies, Inc.TSHA

$68.55M+11.2%

Zevra Therapeutics, Inc.ZVRA

$1.5M-97.6%

LBR

LB Pharmaceuticals IncLBRX

$3.47M—

FAQ

What is Acadia Pharmaceuticals's total debt?

Acadia Pharmaceuticals (ACAD) reported total debt of $73.85M in Q2 2026.

How has Acadia Pharmaceuticals's total debt changed year-over-year?

Acadia Pharmaceuticals's total debt increased by 31.2% year-over-year, from $56.29M to $73.85M.

What is the long-term trend for Acadia Pharmaceuticals's total debt?

Over 5 years (2020 to 2025), Acadia Pharmaceuticals's total debt has grown at a 1.0% compound annual growth rate (CAGR), from $49.55M to $52.19M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.